This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
1. Patients aged ≥ 16 years old.
2. Confirmed diagnosis of acute promyelocytic leukemia (APL) by morphology, flow cytometry, and cytogenetics/molecular testing.
3. ECOG performance status 0-2.
Serum creatinine ≤ 1.5 × ULN
1. Concurrent participation in another interventional clinical trial.
2. History of other malignancies within the past 5 years (except cured basal cell carcinoma or in situ cervical cancer).
3. Severe uncontrolled infection or other serious underlying diseases that may interfere with study treatment or follow-up.
4. Known hypersensitivity to lisaftoclax, ATRA, ATO, or any components of the study regimen.